A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation First-Time-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of Single and Repeat Oral Doses of FDL169 in Healthy Volunteers

Trial Profile

A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation First-Time-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of Single and Repeat Oral Doses of FDL169 in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Apr 2016

At a glance

  • Drugs FDL 169 (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms FTIH
  • Sponsors Flatley Discovery Lab
  • Most Recent Events

    • 07 Apr 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Feb 2016 Planned End Date changed from 1 Sep 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
    • 03 Feb 2016 Planned primary completion date changed from 1 Sep 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top